goals the aim of this study was to assess the efficacy and safety of entericcoated peppermint oil capsules compared with placebo for the treatment of active irritable bowel syndrome ibsbackground ibs is a common disorder that is often encountered in clinical practicemedical interventions are limited and the focus is on symptom controlstudy randomized placebocontrolled trials with a minimum treatment duration of 2 weeks were considered for inclusioncrossover studies that provided outcome data before the first crossover were includeda literature search upto february 2013 identified all applicable randomizedcontrolled trialsstudy quality was evaluated using the cochrane risk of bias tooloutcomes included global improvement of ibs symptoms improvement in abdominal pain and adverse eventsoutcomes were analyzed using an intentiontotreat approachresults nine studies that evaluated 726 patients were identifiedthe risk of bias was low for most of the factors assessedpeppermint oil was found to be significantly superior to placebo for global improvement of ibs symptoms 5 studies 392 patients relative risk 223 95 confidence interval 178281 and improvement in abdominal pain 5 studies 357 patients relative risk 214 95 confidence interval 164279although peppermint oil patients were significantly more likely to experience an adverse event such events were mild and transient in naturethe most commonly reported adverse event was heartburnconclusions peppermint oil is a safe and effective shortterm treatment for ibsfuture studies should assess the longterm efficacy and safety of peppermint oil and its efficacy relative to other ibs treatments including antidepressants and antispasmodic drugs